Investment Director, BioCity

Having spent her career in the BioPharmaceutical industry Claire joined BioCity in 2015, to lead the team and scale up the Investment activity. She has formulated and developed the overall Investment strategy, led the majority of the investments since 2015 and overseen the deployment of the Alderley Park Venture Fund.   Given her broad background, Claire enjoys supporting the portfolio companies in refining strategy and their teams ensuring successful fundraising/licensing and the forming of optimal syndicate partnerships.  Claire currently serves on the boards of a number of the BioCity portfolio companies and acts as the primary liaison with BGF, BioCity’s strategic investor relationship.   Claire is also an advisor with Innovate-UK, on the Enterprise Advisory Board of the University of Liverpool and an investor with Oxford Science Innovation Fund. 

Prior to joining BioCity, Claire held a variety of roles in the Life Science Industry, in the UK and USA covering R & D, Strategy,  Licensing, Business Development and Corporate Investing.  These roles, in 3 major global healthcare organisations (UCB Group, Sanofi-Genzyme and AstraZeneca) spanned diverse therapy areas and modalities (including Cell Tx and recombinant proteins).  She has led complex multi-asset Strategic Alliances (Galderma-AZ), managed asset ‘repositioning’ projects, pioneered new therapy areas leading to clinical candidates and supported on Market products (incl. CartiCelTM, FabraZymeTM).   

Claire received her BSc (Hons) & PhD in Glasgow, has an MBA focused on entrepreneurship and holds a Certificate  in Investment Management and in Company Board Direction


20 May 2021